EUVIMEDEUVIMED entdecken
Open Access

Outcomes of transcatheter aortic valve implantation for native aortic valve regurgitation

Robin Le Ruz, Lionel Leroux, Thibault Lhermusier, Thomas Cuisset, Eric Van Belle, Alain Dibie, Vincenzo Palermo, Didier Champagnac, Jean-François Obadia, Emmanuel Teiger, Patrick Ohlman, Didier Tchétché und 15 weitere

EuroIntervention · 2024-09 · 20 (17) · e1076-e1085

DOI: 10.4244/eij-d-24-00339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EuroIntervention, 2024-09. Verfasst von Robin Le Ruz und 26 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Cardiology Department, Nantes Université, CHU Nantes, L'institut du thorax, Nantes, France. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Insufficiency, Heart Valve Prosthesis, Registries. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Large datasets of transcatheter aortic valve implantation (TAVI) for pure aortic valve regurgitation (PAVR) are scarce. AIMS: We aimed to report procedural safety and long-term clinical events (CE) in a contemporary cohort of PAVR patients treated with new-generation devices (NGD). METHODS: Patients with grade III/IV PAVR enrolled in the FRANCE-TAVI Registry were selected. The primary safety endpoint was technical success (TS) according to Valve Academic Research Consortium 3 criteria. The co-primary endpoint was defined as a composite of mortality, heart failure hospitalisation and valve reintervention at last follow-up. RESULTS: From 2015 to 2021, 227 individuals (64.3% males, median age 81.0 [interquartile range {IQR} 73.5-85.0] years, with EuroSCORE II 6.0% [IQR 4.0-10.9]) from 41 centres underwent TAVI with NGD, using either self-expanding (55.1%) or balloon-expandable valves (44.9%; p=0.50). TS was 85.5%, with a non-significant trend towards increased TS in high-volume activity centres. A second valve implantation (SVI) was needed in 8.8% of patients, independent of valve type (p=0.82). Device size was ≥29 mm in 73.0% of patients, post-procedure grade ≥III residual aortic regurgitation was rare (1.2%), and the permanent pacemaker implantation (PPI) rate was 36.0%. At 30 days, the incidences of mortality and reintervention were 8.4% and 3.5%, respectively. The co-primary endpoint reached 41.6% (IQR 34.4-49.6) at 1 year, increased up to 61.8% (IQR 52.4-71.2) at 4 years, and was independently predicted by TS, with a hazard ratio of 0.45 (95% confidence interval: 0.27-0.76); p=0.003. CONCLUSIONS: TAVI with NGD in PAVR patients is efficient and reasonably safe. Preventing the need for an SVI embodies the major technical challenge. Larger implanted valves may have limited this complication, outweighing the increased risk of PPI. Despite successful TAVI, PAVR patients experience frequent CE at long-term follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve InsufficiencyHeart Valve ProsthesisRegistriesHumansMaleFemaleAgedAged, 80 and overTreatment OutcomeAortic ValveRisk FactorsFrance

Autor:innen und Institutionen

  • Interventional Cardiology Department, Nantes Université, CHU Nantes, L'institut du thorax, Nantes, France.
  • Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France.
  • Department of Cardiology and Cardiovascular Surgery, Hôpital Cardiologique de Haut-Lévêque, Pessac, France.
  • Department of Cardiology, Rangueil University Hospital, Toulouse, France.
  • Centre for Cardiovascular and Nutrition Research, Aix Marseille Université, Marseille, France.
  • University of Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, Lille, France.

Zitieren

APA

Le Ruz, R., Leroux, L., Lhermusier, T., Cuisset, T., Van Belle, E., Dibie, A., Palermo, V., Champagnac, D., Obadia, J. F., Teiger, E., Ohlman, P., Tchétché, D., Le Breton, H., Saint-Etienne, C., Piriou, P. G., Plessis, J., Beurtheret, S., Du Chayla, F., Leclère, M., …, & Of Stop-As And France-Tavi Investigators, O. B. (2024). Outcomes of transcatheter aortic valve implantation for native aortic valve regurgitation. EuroIntervention, 20(17), e1076-e1085. https://doi.org/10.4244/eij-d-24-00339

Vancouver

Le Ruz R, Leroux L, Lhermusier T, Cuisset T, Van Belle E, Dibie A, et al. Outcomes of transcatheter aortic valve implantation for native aortic valve regurgitation. EuroIntervention. 2024;20(17):e1076-e1085. doi:10.4244/eij-d-24-00339

BibTeX
@article{LeRuz2024,
  author = {Le Ruz, Robin and Leroux, Lionel and Lhermusier, Thibault and Cuisset, Thomas and Van Belle, Eric and Dibie, Alain and Palermo, Vincenzo and Champagnac, Didier and Obadia, Jean-François and Teiger, Emmanuel and Ohlman, Patrick and Tchétché, Didier and Le Breton, Hervé and Saint-Etienne, Christophe and Piriou, Pierre-Guillaume and Plessis, Julien and Beurtheret, Sylvain and Du Chayla, Florence and Leclère, Manon and Lefèvre, Thierry and Collet, Jean-Philippe and Eltchaninoff, Hélène and Gilard, Martine and Iung, Bernard and Manigold, Thibaut and Letocart, Vincent and Of Stop-As And France-Tavi Investigators, On Behalf},
  title = {Outcomes of transcatheter aortic valve implantation for native aortic valve regurgitation},
  journal = {EuroIntervention},
  year = {2024},
  volume = {20},
  number = {17},
  pages = {e1076--e1085},
  doi = {10.4244/eij-d-24-00339}
}
Kostenlos starten →